Novartis puts a €2.7bn BET on MorphoSys
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.